Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

To join this study, you would need to be at least 18 years old and have a specific type of lung cancer. This particular cancer must be 'non-small cell lung cancer' that has spread, and tests must show it is 'TTF-1 negative' and doesn't have certain genetic changes (called EGFR mutations or ALK rearrangements).

You would also need to be generally well enough to take part, meaning you can do most of your daily activities without much trouble (doctors call this your ECOG performance status). Your organs like your liver, kidneys, and bone marrow would need to be working well, and your doctors would need to be able to measure your cancer using scans.

Before you start, you'd have meetings with the study team and agree in writing to take part. While some tests can take a little time to come back, treatment generally won't start until all necessary results are in.

Taking part in this study means you would be randomly assigned to one of two treatment groups, like flipping a coin. You wouldn't get to choose which group you're in, and neither would your doctor. Both treatments involve a combination of medicines given through a vein (intravenously). You would have regular visits to the clinic for your treatments, blood tests, and scans to check how you're responding.

The study team will explain exactly how often you'd need to come in and what tests you'd have at each visit. They will also keep track of any side effects you might experience. The total length of your participation in the study, including treatments and follow-up checks, would be explained by your doctor and tailored to your individual needs and how well the treatment works for you.